Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
LUND, Sweden, Nov. 11, 2016 -- Laquinimod
- The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan
- The study results from the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis (RRMS) are expected in the first half of 2017
- The study results from the pivotal clinical Phase 2 ARPEGGIO study, evaluating laquinimod for the treatment of primary progressive multiple sclerosis (PPMS), are expected in the second half of 2017
- Preclinical results concerning laquinimod were presented at the ECTRIMS 2016 Congress held in London, UK, on September 14-17, 2016
- Special Protocol Assessment (SPA) for laquinimod rescinded after discussions with the FDA
ANYARA
- Licensing agreement entered into with NeoTX Therapeutics Ltd
Tasquinimod, Paquinimod (57-57) and SILC (ISI)
- Out-licensing activities are continuing
New share issue
- The Board of Directors has today decided, based on the authorization granted by the Annual General Meeting, to implement a rights issue totaling approximately SEK 55 M
- The issue is at no cost guaranteed in full by the company's largest owner MGA Holding AB
Financial summary
| SEK M | July - Sept | Jan - Sept | Full Year | ||
| 2016 | 2015 | 2016 | 2015 | 2015 | |
| Net sales | 4.1 | 5.2 | 12.0 | 11.3 | 16.3 |
| Operating loss | -11.1 | -22.2 | -41.6 | -149.7 | -177.9 |
| Loss for the period | -12.4 | -23.4 | -44.8 | -152.7 | -193.5 |
| Loss per share, before and after dilution (SEK) | -0.14 | -0.26 | -0.50 | -1.70 | -2.15 |
| Cash and cash equivalents (at the end of the period) | 39.9 | 132.4 | 103.6 | ||
- Operating costs reduced by 67 % (SEK 107.4 M) compared with 2015
- Operations are progressing according to plan pending the Phase 3 results for laquinimod in the first half of 2017
For further information, please contact:
| Tomas Leanderson, President and CEO Tel: +46 46 19 20 95 Hans Kolam, CFO Tel: +46 46 19 20 44 | Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund Tel: +46 46 19 20 00 Fax: +46 46 19 11 05 |
The report is also available at www.activebiotech.com.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/2d930325-016d-4aa6-8819-12468608eb0b
